June 2, 2025 KT-621 / STAT6 Degrader Phase 1 Healthy Volunteer Results Revolutionizing Immunology with Oral Small Molecule Degrader Medicines Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief Executive Officer KT-621 Phase 1 Healthy Volunteer Data Jared Gollob, MD Chief Medical Officer Question and Answer Session 2 Forward Looking Statements This presentation contains forward-looking stat ...

Post-ASCO Update: Phase 3 VERIFY Study Results Protagonist Therapeutics, Inc. Newark, CA June 2, 2025 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business stra ...

I N V E S T O R P R E S E N T A T I O N J U N E 2 0 2 5 DISCLAIMERS FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation, including statements relating to American Healthcare REIT, Inc.'s (the "Company") expectations regarding its performance, interest expense savings, balance sheet, net income or loss per diluted share, NAREIT FFO per diluted share, NFFO per diluted share, NOI growth, total portfolio Same-Store NOI growth, segment-level Same-Store NOI growth or decline, occupancy, r ...

Reviva Pharmaceuticals Reviva | Corporate Presentation 3 Phase 3 RECOVER Open-Label Extension (OLE) Trial of Brilaroxazine in Schizophrenia June 2, 2025 at 8:00am EDT Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's expectations regarding the anticipate ...

Earnings Presentation Q3 Fiscal 2025 Rebecca Gardy Chief Investor Relations Officer Welcome Today's Agenda Mick Beekhuizen Chief Executive Officer Business Update Carrie Anderson Chief Financial Officer Financial Results and Outlook 2 Forward-looking Statements Safe Harbor Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements reflect our current expectations regarding our future results ...

Creating a Leading Global B2B Growth Accelerator Investor Presentation September 5, 2024 © TechTarget 1 Disclaimer (1/2) Additional Information and Where to Find It In connection with the proposed transaction (the "proposed transaction"), Toro CombineCo, Inc. ("NewCo") filed with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (File No. 333-280529) containing a preliminary proxy statement of TechTarget, Inc. ("TechTarget") that also constitutes a preliminary prospectu ...

FINANCIAL RESULTS FY26 1Q SUPPLEMENTAL FINANCIAL PRESENTATION JUNE 2, 2025 SAIC PROPRIETARY INFORMATION I © SAIC. ALL RIGHTS RESERVED FORWARD LOOKING STATEMENTS Certain statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expects," "intends," "projects," "plans," "believes," "estimates," "targets," "anticipates," and similar expressions identify forward-looking statements in this p ...

Forward-looking Statements/Safe Harbor Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in this presentation are forward-looking statements, including statements about: being funded through the initial pivotal readouts for dom, ...

ZL-1310 ASCO 2025 Highlights June 2, 2025 NASDAQ:ZLAB | HKEX:9688 © 2024. Zai Lab. All Rights Reserved. Associate Director of Drug Development, Sarah Cannon Research Institute Forward-Looking Statements This presentation contains forward-looking statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding product candidates in our pipeline including ZL-1310 and related clinical trials and preclinical studies, the potential benefits and safety an ...

SCIENTIFIC WEBINAR 2025 PC111 - A New Drug Candidate for Rare Skin Diseases: Pemphigus and SJS/TEN Pincell Acquisition Option 1 Agenda Ø Overview of Pemphigus and SJS/TEN Symptoms, implications and patho-mechanisms Ø Overview of Current Treatment Landscape Ø PC111 Deep Dive: -- Mechanism of Action -- Achievements to Date -- Comparison to Current SOC -- Safety Profile -- Combination with Existing Therapies (Risks/Benefits) -- Development Plan -- Challenges in Conducting Rare Disease Clinical Trials Ø Commerc ...